Y Intercept Hong Kong Ltd Grows Stock Position in Olema Pharmaceuticals, Inc. $OLMA

Y Intercept Hong Kong Ltd grew its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 143.0% in the 1st quarter, Holdings Channel.com reports. The fund owned 90,375 shares of the company’s stock after buying an additional 53,176 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Olema Pharmaceuticals were worth $1,347,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC increased its holdings in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares in the last quarter. Torren Management LLC purchased a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $88,000. Nisa Investment Advisors LLC grew its position in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after purchasing an additional 1,169 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Olema Pharmaceuticals in a report on Thursday, March 19th. They issued a “buy” rating and a $40.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. JPMorgan Chase & Co. raised their target price on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Citigroup boosted their price target on Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA traded down $0.37 on Friday, hitting $11.91. 927,028 shares of the company’s stock traded hands, compared to its average volume of 1,877,591. The firm’s 50-day moving average price is $12.17 and its two-hundred day moving average price is $18.07. The firm has a market capitalization of $1.04 billion, a PE ratio of -5.90 and a beta of 2.00. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a 1-year low of $4.37 and a 1-year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). As a group, analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.